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INTRODUCTION
Therapies with biological drugs repre-
sent a very important pharmacological
resource available to the rheumatologist
and all those patients who see compro-
mised the quality of their life because of
a lack of response to traditional thera-
pies. The Italian Society of Rheumatology
(SIR) is strongly committed to ensure
patient access to the best treatment avail-
able, paying attention to limited economic
resources. The new Guidelines of the SIR
go in this direction. With the term “bio-
logical drugs” are considered all those new
generation drugs designed to act only on
a single structure (which may be a pro-
tein, a receptor, or even a DNA sequence)
by increasing the efficacy of the therapy
and by reducing, at the same time, the
undesired effects. Today there are biolog-
ical drugs available against autoimmune
diseases (for example, lupus, rheuma-
toid arthritis, psoriasis), chronic inflam-
matory diseases of the intestine (such as
Crohn’s disease and ulcerative colitis), and
some types of cancer. This study takes
its cue from Commissary Decree n. 26
of 14 March 2012 (region of Campania,
Italy), on the appropriateness of biolog-
ics used to treat psoriasis and psoriatic
arthritis, rheumatoid arthritis, ankylos-
ing spondylitis, and Chronic inflamma-
tory diseases of the intestinal tract both
in adult and pediatric patients, exclud-
ing therefore biological drugs prescribed
for tumor pathologies. The objective of
biologics is to reach the cells or diseased
structures, by acting directly on these
without damaging healthy cells. To achieve
that goal it was thought to use the defenses
of our organism, namely antibodies, mod-
ifying them in such a way as to make
them capable to recognize as aggressors
structures diseased or proteins involved
in the pathological process. As in the
case of the studied drugs to treat autoim-
mune diseases, such as rheumatoid arthri-
tis, that are programmed for “attacking”
the pro-inflammatory cytokines released
by inflamed cells, so as to block the inflam-
mation. The purpose of this study is to
compare the requirements of biological
drugs for the mentioned diseases, mon-
itor accurately spending of these drugs
with a high cost and check constantly
the appropriateness prescriptive with the
adoption of the regional tab for the
prescription from the centers of ref-
erence having the requirements of the
law.
MATERIALS ANDMETHODS
In the Pharmacy of the District of
Herculaneum (Naples, Italy) we have acti-
vated by April 2012, an archive H of bio-
logical drugs purchased and dispensed. All
the regional cards, comprising the biolog-
ical drugs prescribed, received during the
period April 2012–September 2012 were
examined. These cards are the pre-printed
forms each for a particular therapeutic
indication for which the biologic drug is
prescribed. It consists of four sections. The
first section shows the data of the refer-
ence center and the prescribing physician,
the second section of the card shows the
generality of the patient, the third section
includes the diagnosis and the biologic
drug prescribed with specified the dosage
and the mode of administration while the
fourth section is for recording the delivery
of the drug by the pharmaceutical service
of the ASL of residence of the assisted. This
card is valid for 3months and also contains
a small statement of acquisition by the
prescribing physician, the informed con-
sent of the patient. The archive, on excel
sheet, has allowed us to have sure data
and immediate on the number of therapies
with each drug monitored and has been
created so that each patient is recorded
and catalogued on the basis of biologic
drug prescribed, dosage, and expenditure
calculated for single vial delivered.
RESULTS
During the reporting period April
2012–September 2012 were treated a
total of 79 patients with autoimmune
diseases or chronic inflammatory bowel
disease. The biologics prescribed were
Etanercept fl 50mg, Adalimumab fl 40mg,
Infliximab fl 100mg, Tocilizumab fl
80mg–200mg–400mg, Ustekimumab fl
90mg, Certolizumab fl 200mg, Abatacept
fl 250mg. Specifically, the data obtained
were: 41 patients treated with etanercept
fl 50mg and delivered 396 vials in all for
a total expenditure of about C94,799. Of
the 41 patients treated with etanercept
fl 50mg, 20 were suffering from psoriatic
arthritis, 12 from rheumatoid arthritis and
9 suffering from psoriasis; in addition, 20
patients were treated with Adalimumab fl
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40mg to which were delivered 110 vials for
a total expenditure of about C51,412. Of
the 20 patients treated with Adalimumab fl
40mg, 7 were suffering from rheumatoid
arthritis, 7 psoriatic arthritis, 4 psoriasis
and 2 suffering from Crohn’s disease; were
also 4 patients treated with Infliximab fl
100mg to which were delivered 28 vials
in all for a total expenditure of about
C13,055. Of the 4 patients treated with
Infliximab fl 100mg, 3 were with psoriatic
arthritis and 1 suffering from psoriasis;
in addition, 5 patients were treated with
Tocilizumab fl 80mg, 200mg, and 400mg,
which were delivered 53 vials in all for a
total expenditure of about C12,863 all
suffering from rheumatoid arthritis; in
addition, 2 patients with both psoria-
sis were treated with Ustekimumab fl
90mg to which were delivered 2 vials
in everything for a total expenditure of
about C5686; other 2 patients with both
rheumatoid arthritis were treated with
Certolizumab fl 200mg to which were
delivered 10 vials for a total expendi-
ture of about C3415; finally, 5 patients
were treated with Abatacept fl 250mg
to which were dispensed in all 39 vials
for a total expenditure of about C12,600
and all suffering from rheumatoid arthri-
tis. The pharmaceutical spending total,
incurred to acquire biological drugs to
assisted the District of Herculaneum, was
approximately C197,000 and the dis-
eases treated were rheumatoid arthritis,
psoriatic arthritis, psoriasis and Crohn’s
disease for a total of 79 patients treated
on a population of 57,000 inhabitants
in the territory of Herculaneum (Naples,
Italy). Rheumatoid arthritis has resulted
in the pathology more treated with 31
patients, 30 patients instead with psoriatic
arthritis, 16 affected by psoriasis and 2
suffering from Crohn’s disease. The most
prescribed drug was Etanercept fl 50mg
which has had an impact on total expen-
diture for the approximately 48%, while
Adalimumab fl 40mg has had an impact
on total expenditure for the 26% approx-
imately. The Infliximab fl, Tocilizumab fl,
and Abatacept fl have contributed each
for the 6.5% while Ustekimumab and
Certolizumab have participated on total
expenditure in a manner quite negligible
around 2–3%.
DISCUSSION
The pharmaceutical service in the District
of Herculaneum did spent in the 6-month
period fromApril 2012 to September 2012,
in all about C2,000,000 for the pharma-
ceutical care of all the sick afferent to the
District. If one considers that it is only for
the purchase of biological drugs, for the
aforementioned pathologies, were spent
approximately C197,000 or almost 10%
of the total, we can actually conclude by
saying that the biological drugs have a
high impact on pharmaceutical spending
overall, therefore, a careful monitoring is
really necessary for the purpose of improv-
ing the quality of care to obtain a more
efficient management of the resources
available. The National Guidelines and
International, based on scientific evidence,
define precise criteria to minimize the
variability in clinical practice, supporting
the rheumatologists, in their daily work,
in finding the best treatment that takes
into account the specificity of the individ-
ual patient, avoiding delays in the choice
of therapy most suited and optimizing
especially the use of drugs biologists with
obvious repercussions on health spending.
The objective is to identify patients eligi-
ble for treatment with biological drugs,
with the aim to identify those people who,
by undergoing biological therapy, may
actually benefit from them. The introduc-
tion of biological drugs in clinical practice
has certainly represented an absolute rev-
olution in rheumatology, both for the
innovative design of aim of the treatment
on specific targets fundamental in the
pathogenesis of the disease, and both for
the undoubted efficacy demonstrated by
these drugs against the traditional thera-
pies. The extensive use of this therapeutic
approach is however, still limited by sev-
eral factors, such as the lack of information
about the security in the long term, the
need for a monitoring of patients more
attentive and narrow, the limitations in
the selection of subject treatable set by the
criteria of inclusion and exclusion from
treatment and, no less important, the
absolute cost of biological medicines, as
demonstrated in this study. For this ther-
apy with biological and still reserved for
the prescription of rheumatologic centers
of excellence, through a careful selection
of cases in order to identify the patients
most suited to this therapeutic regimen.
It is obviously desirable that in the com-
ing years a better knowledge of long-term
effects of biological drugs and a better eco-
nomic planning of their use can increase
progressively the use, extended to cover a
proportion of patients increasingly wide.
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